BioWorld

Oct. 12, 2007

Cortex Falls As FDA Rejects CX717 Phase IIb In ADHD

Shares of Cortex Pharmaceuticals Inc. plunged 59 percent after the FDA rejected a proposal for a Phase IIb trial of lead ampakine compound CX717 in attention deficit hyperactivity disorder. (BioWorld Today) Read More

Missed Endpoint Won't Doom Future of Gattex, NPS Vows

CombinatoRx Stock Offering Nets $33M For Thick Pipeline

Hemispherx Files Ampligen NDA: First Therapy For CFS?

Pharmaxis Raises $45M To Push Late-Stage Pulmonary Drugs

CuraGen Shuts Down Program Following 2nd Phase II Failure

Other News To Note

Appointments And Advancements

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...